B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

DLD

MOLECULAR TARGET

dihydrolipoamide dehydrogenase

UniProt: P09622NCBI Gene: 17385 compounds

DLD (dihydrolipoamide dehydrogenase) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting DLD

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1egcg0.691
2Rutin0.691
3Oxaprozin0.691
4Pioglitazone0.691
5streptonigrin0.691

About DLD as a Drug Target

DLD (dihydrolipoamide dehydrogenase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented DLD interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

DLD inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.